Key Points
- SVP Mary Elizabeth Henderson sold 2,238 shares at an average price of $169.51 for a total of $379,363.38, cutting her stake by 10.29% to 19,508 shares valued at about $3.31M.
- Wall Street consensus is a Moderate Buy with a consensus price target of $200.47, and several analysts have recently raised targets (e.g., Wells Fargo to $235, Morgan Stanley to $205, Robert W. Baird to $209).
- The stock has a market cap of $10.02B, a negative P/E (-27.16), a 12‑month range of $95.49–$182.99, and roughly 89.14% institutional ownership.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) SVP Mary Elizabeth Henderson sold 2,238 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $169.51, for a total value of $379,363.38. Following the transaction, the senior vice president directly owned 19,508 shares in the company, valued at approximately $3,306,801.08. The trade was a 10.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Jazz Pharmaceuticals Price Performance
NASDAQ JAZZ opened at $164.89 on Friday. The stock has a market cap of $10.02 billion, a price-to-earnings ratio of -27.16, a PEG ratio of 3.71 and a beta of 0.30. Jazz Pharmaceuticals PLC has a 12 month low of $95.49 and a 12 month high of $182.99. The company's 50 day moving average is $150.37 and its two-hundred day moving average is $128.70. The company has a current ratio of 1.65, a quick ratio of 1.44 and a debt-to-equity ratio of 1.09.
Wall Street Analysts Forecast Growth
Several research analysts recently weighed in on JAZZ shares. Wells Fargo & Company upped their target price on shares of Jazz Pharmaceuticals from $170.00 to $235.00 and gave the stock an "overweight" rating in a report on Tuesday, November 18th. JPMorgan Chase & Co. dropped their price objective on Jazz Pharmaceuticals from $204.00 to $199.00 and set an "overweight" rating for the company in a research note on Monday, October 27th. Needham & Company LLC reiterated a "buy" rating and set a $202.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. Morgan Stanley lifted their target price on Jazz Pharmaceuticals from $185.00 to $205.00 and gave the company an "overweight" rating in a research note on Monday, November 17th. Finally, Robert W. Baird upped their price target on Jazz Pharmaceuticals from $160.00 to $209.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 18th. Thirteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $200.47.
View Our Latest Analysis on JAZZ
Institutional Investors Weigh In On Jazz Pharmaceuticals
A number of hedge funds have recently made changes to their positions in JAZZ. Philip James Wealth Mangement LLC grew its stake in shares of Jazz Pharmaceuticals by 42.0% during the second quarter. Philip James Wealth Mangement LLC now owns 15,797 shares of the specialty pharmaceutical company's stock valued at $1,676,000 after buying an additional 4,675 shares during the last quarter. State of Alaska Department of Revenue grew its position in Jazz Pharmaceuticals by 75.1% in the 2nd quarter. State of Alaska Department of Revenue now owns 57,933 shares of the specialty pharmaceutical company's stock valued at $6,147,000 after acquiring an additional 24,850 shares during the last quarter. Inspire Investing LLC purchased a new stake in Jazz Pharmaceuticals in the first quarter worth $689,000. Baird Financial Group Inc. bought a new stake in shares of Jazz Pharmaceuticals during the first quarter worth $539,000. Finally, Kennedy Capital Management LLC purchased a new stake in shares of Jazz Pharmaceuticals during the second quarter valued at $1,100,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.
About Jazz Pharmaceuticals
(
Get Free Report)
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
